Yokohama City

Jan 22, 2025 | bmccancer.biomedcentral.com | Yokohama City

Of the 935 patients with primary NSCLC during the study period, 116 were diagnosed with pathological stage III after surgical resection. Among these, 10 who underwent sublobar resection or biopsy, 1 who did not undergo mediastinal lymph nodal dissection, and 8 who had undergone R1 or R2 resection were excluded. Consequently, 97 patients were included in the final study cohort (Fig. 1). Lobectomy, bilobectomy, and pneumonectomy were performed in 94, 3, and 0 patients, respectively.

Nov 29, 2024 | bmccancer.biomedcentral.com | Yokohama City

ReferencesSung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. https://doi.org/10.3322/caac.21660 ,PMID. Article  CAS  PubMed  Google Scholar  Rawla P, Sunkara T, Gaduputi V. Epidemiology of pancreatic cancer: global trends, etiology and risk factors. World J Oncol. 2019;10:10–27. https://doi.org/10.14740/wjon1166 ,PMID.

Nov 28, 2024 | link.springer.com | Yokohama City

AbstractReports on the association of perioperative nutritional and inflammatory status with the clinical course of adjuvant chemotherapy did not include neoadjuvant chemotherapy. We aimed to clarify the mechanism by which perioperative nutritional and inflammatory status affect the clinical course of postoperative adjuvant chemotherapy in patients with pancreatic cancer.

Nov 28, 2024 | academic.oup.com | Yokohama City

The EF-14 clinical trial demonstrated the safety and efficacy of tumor treating fields (TTFields) for newly diagnosed glioblastoma. This study aimed to clarify the current status, safety, and efficacy of TTFields in Japanese patients who meet the EF-14 inclusion criteria. This was a multicenter retrospective cohort study. Background, treatment, and outcome data of patients who satisfied the inclusion criteria of the EF-14 trial were collected from 45 institutions across Japan.

Nov 20, 2024 | alzres.biomedcentral.com | Yokohama City

A total of 165 participants were initially enrolled in this study; 155 participants (93.9%) possessed complete information and were therefore included in the final dataset for analysis. Reasons for exclusion included ineligibility due to exclusion criteria (n = 1), mortality (n = 2), withdrawal of consent (n = 2), or failure to undergo PET within the specified timeframe (n = 5).